An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects
Phase of Trial: Phase 0
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Psoriasis; Transplant rejection
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Auritec Pharmaceuticals
- 10 Jan 2019 Status changed from active, no longer recruiting to completed.
- 07 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Oct 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 16 Aug 2018 to 15 Nov 2018.